Tests HS-10374 tablets in adults with mild-to-moderate plaque psoriasis
Tests HS-10374 tablets against placebo in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06926582, who can take part
Where in China
- Shanghai Dermatology HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hansoh BioMedical R&D Company
- Trial code
- NCT06926582
- Record updated
- 13 April 2025
- Original description
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.Read full original descriptionShow less
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Clinical Efficacy and Safety of HS-10374 in Adult Patients With Mild-to-moderate Plaque Psoriasis
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.
Inclusion: Male or female subjects between the ages of 18-70 years; Diagnosis of plaque psoriasis for at least 6 months; sPGA score of 2-3, BSA 2-15%, PASI score 2-15; Subject must be inadequately controlled with, or intolerant of at least one topical therapy.
Exclusion: Diagnosis of non-plaque psoriasis or drug-induced psoriasis; Prior exposure to TYK2 inhibitors; Have received the prohibited treatment during the protocol required washout period; Recent history of infection, history or risk of serious infection; Any major illness or evidence of unstable condition of major organ systems including psychiatric disease; Any condition possibly affecting the PK process of the study drug; Evidence of other skin conditions that would interfere with the evaluation of psoriasis; History of hypersensitivity to the ingredients of study drugs, history of anaphylaxis; Any significant laboratory or procedure abnormalities that might place the subject at unacceptable risk during this study period.